Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PAVM

PAVM - PAVmed Inc Stock Price, Fair Value and News

$8.05-0.60 (-6.94%)
Market Closed

50/100

PAVM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

50/100

PAVM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$8.27

Target 3M

$8.93

Target 6M

$8.7

PAVM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PAVM Price Action

Last 7 days

-33.2%

Last 30 days

-5.2%

Last 90 days

-36.6%

Trailing 12 Months

-58.3%

PAVM RSI Chart

PAVM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PAVM Valuation

Market Cap

173.5M

Price/Earnings (Trailing)

56.06

Price/Sales (Trailing)

20.13

EV/EBITDA

105.94

Price/Free Cashflow

-47.83

PAVM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$8.27

Target 3M

$8.93

Target 6M

$8.7

PAVM Fundamentals

PAVM Revenue

Revenue (TTM)

8.6M

Rev. Growth (Yr)

-76.71%

Rev. Growth (Qtr)

-94.83%

PAVM Earnings

Earnings (TTM)

3.1M

Earnings Growth (Yr)

-108.36%

Earnings Growth (Qtr)

54.84%

PAVM Profitability

Operating Margin

97.91%

EBT Margin

16.59%

Return on Equity

9.52%

Return on Assets

8.13%

Free Cashflow Yield

-2.09%

PAVM Investor Care

Shares Dilution (1Y)

115.43%

Diluted EPS (TTM)

18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20257.0M9.2M8.6M0
20243.0M3.8M3.7M4.8M
2023634.0K800.0K1.5M2.5M
2022469.3K438.5K407.8K377.0K
2021000500.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About PAVmed Inc

PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
 CEO
 WEBSITEpavmed.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES124

PAVmed Inc Frequently Asked Questions

PAVM is the stock ticker symbol of PAVmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of PAVmed Inc is 173.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PAVM's fair value in chart for subscribers.

The fair value guage provides a quick view whether PAVM is over valued or under valued. Whether PAVmed Inc is cheap or expensive depends on the assumptions which impact PAVmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PAVM.

As of Wed Jan 28 2026, PAVM's PE ratio (Price to Earnings) is 56.06 and Price to Sales (PS) ratio is 20.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PAVM PE ratio will change depending on the future growth rate expectations of investors.